Horizon Pharma signs $1.1bn deal to buy Hyperion
Dublin-based Horizon Pharma is to acquire Hyperion Therapeutics in an all-cash deal worth $1.1bn or $46.00 per share, about a 35% premium to its average share price for the past 60 days.
Dublin-based Horizon Pharma is to acquire Hyperion Therapeutics in an all-cash deal worth $1.1bn or $46.00 per share, about a 35% premium to its average share price for the past 60 days.